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A major focus in development of novel therapies for Huntington’s disease (HD) is iden-
tification of treatments that reduce the burden of mutant huntingtin (mHTT) protein in 
the brain. In order to identify and test the efficacy of such therapies, it is essential to 
have biomarkers that are sensitive to the effects of mHTT on brain function to determine 
whether the intervention has been effective at preventing toxicity in target brain systems 
before onset of clinical symptoms. Ideally, such biomarkers should have a plausible 
physiologic basis for detecting the effects of mHTT, be measureable both in preclinical 
models and human studies, be practical to measure serially in clinical trials, and be 
reliably measurable in HD gene expansion carriers (HDGECs), among other features. 
Quantitative electroencephalography (qEEG) fulfills many of these basic criteria of a “fit-
for-purpose” biomarker. qEEG measures brain oscillatory activity that is regulated by the 
brain structures that are affected by mHTT in premanifest and early symptom individuals. 
The technology is practical to implement in the laboratory and is well tolerated by humans 
in clinical trials. The biomarkers are measureable across animal models and humans, 
with findings that appear to be detectable in HDGECs and translate across species. 
We review here the literature on recent developments in both preclinical and human 
studies of the use of qEEG biomarkers in HD, and the evidence for their usefulness as 
biomarkers to help guide development of novel mHTT lowering treatments.
Keywords: Huntington’s disease, mutant huntingtin, huntingtin aggregates, quantitative electroencephalography, 
biomarkers, human, mouse, electrophysiology
2Leuchter et al. qEEG in HD
Frontiers in Neurology | www.frontiersin.org March 2017 | Volume 8 | Article 91
iNTRODUCTiON
Many current strategies for the treatment of Huntington’s disease 
(HD) are focused on development of agents to lower mutant 
huntingtin (mHTT) protein burden. Although the precise role 
of mHTT aggregates in HD neuropathology has not been com-
pletely elucidated, studies in HD transgenic mice have shown a 
correlation between mHTT aggregation and development of the 
phenotype (1). The presence of mHTT adversely affects the func-
tion of multiple cell lines, particularly neurons, from early human 
development through phenoconversion to the illness. Therefore, 
chronic reduction in the levels of mHTT prior to the onset of 
symptoms could presumably prevent the development or reduce 
the severity of many of the manifestations of HD.
Biomarkers play a unique role in research aimed at mHTT 
reduction. In contrast to most degenerative diseases of the cen-
tral nervous system, highly specific biomarkers for HD already 
exist: the genetic mutation that leads to production of mHTT (a 
trinucleotide repeat expansion) has been identified. It is already 
possible to identify individuals who will develop the illness based 
on the presence of the mutation, estimate their age of disease 
onset (by measuring length of the expansion), and to quantify 
levels of mHTT in a subject’s cerebrospinal fluid and body tissues.
Although these biomarkers are highly specific, they are not 
entirely fit-for-purpose for the development of mHTT lowering 
therapeutic strategies. While mHTT is produced throughout life, 
the developmental stage at which the protein becomes toxic varies 
across organ systems, and even within a particular organ. mHTT 
toxicity is remarkably pleiotropic (2, 3), disrupting a broad range 
of cellular processes including energetics (i.e., mitochondrial 
function), transcriptional regulation (i.e., expression of neuro-
trophic factors and G protein-coupled receptors), synaptic neu-
rotransmission (i.e., vesicular trafficking), and synaptic plasticity 
(2, 4–6). It remains unclear at what stage of development mHTT 
begins to elicit these different forms of toxicity and whether dif-
ferent brain regions (i.e., cortex, striatum, and thalamus) have dif-
ferential sensitivities to mHTT that may change over the course 
of nervous system development. Therefore, while it is feasible to 
measure mHTT levels, it is difficult to use mHTT levels alone 
to gauge the efficacy of mHTT lowering strategies in achieving 
clinically meaningful outcomes.
The Huntingtin-Lowering Biomarker Task Force (7) posited 
nine criteria for biomarkers of sufficient reliability to be utilized 
in trials of mHTT lowering agents. They concluded that such 
biomarkers should share several characteristics: (1) biological 
plausibility (a plausible physiologic connection between bio-
marker readout and change in mHTT level); (2) technologic 
feasibility (adaptable to both humans and animal models); (3) 
measurable in humans (useful in humans participating in clinical 
trials); (4) repeatable within subjects (good test–retest reliability 
with serial use during treatment); (5) reliably measurable in HD 
gene expansion carriers (HDGECs) (applicable to pre-manifest 
and early- to mid-stage manifest HD); (6) signal metrics (good 
signal-to-noise ratio and dynamic range, applicable to relatively 
small sample sizes, and strong inter- and intra-subject and site 
reliability); and (7) measurable in preclinical HD models (quan-
tifiable in HD animal models).
Quantitative electroencephalography (qEEG) biomarkers 
fulfill many of the criteria outlined above for use in research and 
clinical trials to develop mHTT lowering treatments. qEEG bio-
markers have a plausible physiologic link to the effects of mHTT 
lowering because brain oscillatory activity is regulated by the 
thalamocorticostriatal systems that show preclinical and early-
disease changes in HD. The technology is feasible to implement 
across species and can easily be performed serially in the course 
of clinical trials. A key question is whether reliable and reproduc-
ible biomarker signals can be measured in preclinical and clinical 
studies involving HD and HDGECs. We review here the animal 
and human literature on qEEG biomarkers and discuss the role 
that these biomarkers may fulfill in trials aimed at development 
of mHTT lowering treatments.
MeTHODS
We performed searches on PubMed for the years 2000–2016 
aimed at identification of all studies that examined qEEG bio-
marker features in preclinical and clinical models of HD. All 
searches in the series included (EEG OR EEG Mapping OR qEEG) 
AND (Huntington’s disease OR Huntington’s OR huntington 
OR huntington disease). Additional query terms for individual 
searches included biomarker, preclinical, power spectral analysis, 
neural networks, LORETA, (Mouse OR Mice) AND (R6/2 OR 
zQ175), (monkey OR non-human primate), rat, sheep, minipig, 
and animal model. Single-subject case studies and publications 
that met PubMed search criteria but did not discuss EEG findings 
were excluded from our results. A total of 37 entries were prelimi-
narily identified, of which 21 met our criteria for inclusion in this 
review. Further elimination of duplicated entries from different 
searches yielded 16 unique publications for review.
ReSULTS
Preclinical Studies
Rodent Models
The most common models of HD utilized in preclinical studies 
involve transgenic mice, particularly R6/2 and zQ175 (8, 9). These 
models allow for the relatively rapid evaluation of biomarkers 
from shortly after birth to symptom onset and recapitulate char-
acteristics of the disease seen in humans (9, 10). The R6/2 mouse 
carries a fragment of exon 1 of the human mHTT gene with an 
expanded CAG-repeat segment that shows relatively early onset 
of rapidly progressive symptoms (10, 11). The original R6/2 mice 
had a CAG repeat length of approximately 150, and a lifespan 
of roughly 15 weeks, with onset of symptoms at approximately 
6–7 weeks of age. Contrary to expectation, increasing the CAG 
repeat length in R6/2 mice led to a lessening of symptom sever-
ity and longer lifespan. Current studies frequently utilize R6/2 
mice with a CAG repeat length of 250 (12). The zQ175 knock-in 
(KI) mouse model, which expresses the mHTT gene within the 
mouse genomic context (13), allows for further examination over 
the course of a slower progression that more closely follows the 
course of human disease (13–16). The resulting neural circuitry 
disruptions are observable through qEEG.
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Table 1 shows results of the PubMed search of articles discuss-
ing qEEG in R6/2 and zQ175 mice, as well as tgHD and BACHD 
rats. Five studies examined qEEG findings in R6/2 mice, compar-
ing qEEG recorded from cortical or dural electrodes with those 
seen in wild-type (WT) mice across the sleep–wake cycle. Fisher 
et  al. (17) characterized sleep qEEG findings from dural screw 
electrodes following periods of sleep deprivation and found both 
a progressive reduction of sleep time and fragmentation of sleep 
in R6/2 mice when compared to WT mice (17). These progressive 
changes were observable as early as 13 weeks of age (17). Similar 
findings were reported by Kantor et al. (18), although this group 
detected differences from WT by 9 weeks of age (18). In addition 
to diurnal patterns, Fisher and colleagues examined the circadian 
measure of body temperature and found that R6/2 mice also 
exhibited disruption of this regulation by 13 weeks (17).
In both of these studies, circadian disruptions were accom-
panied by increases in high-frequency oscillatory activity 
(high-beta and gamma) and decreases in delta and theta absolute 
power in the week nine qEEG recordings (17, 18). Fisher and 
colleagues (17) reported that the qEEG alterations emerged at 
9  weeks (4  weeks earlier than the diurnal disturbances) (17), 
while Kantor’s group observed qEEG differences simultaneously 
with diurnal disturbances (18). Because both of these groups of 
investigators performed their first qEEG recordings at 9 weeks 
of age, it is unknown whether any qEEG or diurnal disturbances 
would be observable prior to this age. The detection of qEEG 
differences prior to or in the earliest stages of symptoms suggests 
that qEEG differences may be detectable in HDGECs (17, 18).
Callahan and Abercrombie (20) examined the oscillatory 
signals arising both in the subthalamic nucleus (STN) and the 
cortex in anesthetized R6/2 mice using local field potentials 
(LFPs) and cortical recordings (20). They saw a decrease in 
absolute delta power and an increase in absolute beta and 
gamma power, corroborating previous findings. These investiga-
tors also reported reduced coherence between STN and cortex 
in the delta frequency band during synchronized, though not 
desynchronized cortical activity. Previous examination of LFPs 
in R6/2 mice showed high-frequency (32 Hz) oscillations during 
rest and grooming, while WT mice did not. Interestingly, when 
R6/2 mice engaged in exploration, LFPs synchrony between 
motor cortex and dorsal striatum declined, particularly at high 
frequencies (22).
Kantor and colleagues (19) performed a follow-up study 
of their previously observed qEEG and behavioral changes in 
R6/2 mice following the administration of hypnotic agents (19). 
Aberrant gamma oscillations were dampened by both amitripty-
line and zolpidem administration in a dose-dependent manner. 
They also found that the abnormally high amount of REM sleep 
previously noted by both Kantor et al. (18) and Fisher et al. (17) 
was reduced. Zolpidem administration reduced the amount of 
REM sleep in R6/2 mice for 2–3 h, but had no effect on WT mice. 
Amitriptyline reduced the amount of REM sleep in both R6/2 and 
WT mice for at least 6 h. Amitriptyline reduced low frequency 
oscillatory power during NREM sleep in both WT and R6/2 
mice, in addition to lengthening and consolidating NREM sleep. 
Zolpidem, however, induced an increase in absolute delta power 
and altered NREM sleep only in WT mice, not in the R6/2 model. 
These findings suggest a pharmacodynamic difference that may 
be related to the HD genotype.
Fisher and colleagues (16) performed a follow-up to their ear-
lier R6/2 study in which they examined both heterozygous (Het) 
and homozygous (Hom) zQ175 mouse models (16). Findings in 
the Hom zQ175 model were similar to those reported earlier in 
R6/2 mice although with later onset of diurnal disturbances (24 
vs. 13 weeks) and core temperature regulation (16 vs. 13 weeks). 
Diurnal and body core temperature discrepancies were not 
observed between Het and WT mice, though Het mice had signifi-
cantly lower weight than WT mice by 29 weeks. qEEG differences 
were observed in both Het and Hom mice relative to WT. In both 
Het and Hom, absolute delta power decreased, absolute beta and 
gamma power increased, and peak theta frequency shifted lower 
relative to WT. These described spectral shifts were greater for the 
Hom mice than the Het. The conservation of these observations 
in different mouse lines suggests that they are characteristics of 
the disease that are expressed across different transgenic models, 
which is encouraging for identification of biomarkers that are 
sensitive to the underlying mechanisms of cell pathology across 
models. Additionally, the gene dosage dependence of the qEEG 
power suggests a potential correlation between the magnitude of 
the disruption of normal oscillatory patterns and severity of the 
underlying pathology, a desirable characteristic of the biomarker.
However, the zQ175 Het model in this study showed no symp-
toms of disease onset, motor or otherwise, beyond the change 
in body weight (16). The EEG disturbances observed in the Het 
mice suggest HD pathology, but the link to phenoconversion 
remains unclear. Previous work has demonstrated that Het mice 
develop behavioral symptoms, and reason for the lack of appar-
ent symptoms in this particular study is unknown (13, 15, 23). 
Further research is needed to establish a closer linkage between 
the symptoms and qEEG biomarkers in the zQ175 Het model. 
Such longitudinal research may provide valuable insight into the 
alterations of qEEG biomarkers as a function of disease severity.
Rat models of HD have been examined in addition to the 
murine models described earlier, although relatively little qEEG 
work has been performed in rats at this time (14, 21, 24). Miller 
et al. (21) performed extracellular recordings of transgenic mice 
and rats (21). Specifically, they examined neuronal spike activity 
in both R6/1 and R6/2 mice, as well as KI mice and transgenic 
(tgHD) rats. Recordings were performed in the striatum in all 
models, the prefrontal cortex and primary motor cortex of 
R6/2 mice, and the prefrontal cortex of KI mice. LFPs also were 
measured in the R6/2 striatum. Significant differences in spiking 
activity were detected between all models and their respective 
WT littermates. These differences were seen in burst firing 
declines, inter-spike-interval variation coefficient reduction, and 
of significant note to this review, a decrease in delta and theta 
relative power and increase in relative gamma power in LFP 
recordings from R6/2 striata during rest.
Nagy et al. (14) examined hippocampal and auditory cortex 
absolute gamma power using LFPs in both zQ175 mice and 
BACHD rats to measure auditory gating (14). They found 
impairment of auditory gating in Het and Hom zQ175 mice 
as well as BACHD rats. They also found elevated hippocampal 
gamma power in Hom zQ175 mice relative to WT and decreased 
TABLe 1 | Literature review results for qeeG biomarkers in rodents.
Reference Year Rodent 
strain(s)
Recording site Measure electrophysiological finding(s) Behavioral correlation(s)
Kantor et al. (19) 2016 R6/2 mice Dural screws qEEG Gamma absolute power was higher in R6/2 mice during REM and 
suppressed upon administration of zolpidem or amitriptyline (p < 0.01)
Sleep/wake abnormalities were corrected in 
a dose-dependent manner and correlated 
with qEEG correctionsAbsolute delta power was increased by zolpidem in wild-type (WT) mice, not 
in R6/2, during REM (p < 0.01)
1–5 Hz (delta/alpha) and 3–7 Hz (delta/alpha/theta) absolute powers were 
decreased by amitriptyline in WT and R6/2, respectively (p < 0.01)
Fisher et al. (16) 2016 zQ175 mice Dural screws qEEG Absolute delta power lower in Het and Hom zQ175 relative to WT (p < 0.01) Sleep/wake amount and body temperature 
regulation disrupted in Hom, qEEG markers 
were observed prior to disruptions. No 
differences observed between Het and WT, 
though qEEG differences observed in Het 
were observed prior to previously reported 
motor disturbances
Absolute beta and gamma power higher in Het and Hom zQ175 relative to 
WT (p < 0.01)
Peak theta frequency was lower in Het and Hom zQ175 relative to WT 
(p < 0.05)
Callahan and 
Abercrombie (20)
2015 R6/2 mice Cortex ECoG and local 
field potentials 
(LFPs) (of STN)
Absolute delta and theta power lower in R6/2 mice relative to WT (p < 0.01) None
Absolute beta (p < 0.01) and gamma (p < 0.05) power higher in R6/2 mice 
relative to WT
Nagy et al. (14) 2015 zQ175 mice and 
BACHD rats
Hippocampus LFP Absolute gamma power higher in Hom zQ175 relative to WT (p < 0.05) None
Absolute gamma power lower in BACHD rats relative to WT (p < 0.05)
PDE9A inhibitor lowered WT rat absolute gamma power to BACHD levels 
(p < 0.05)
PDE9A inhibitor had no effect on zQ175 relative to WT (p < 0.05)
Kantor et al. (18) 2013 R6/2 mice Dural screws qEEG Absolute delta power lower in R6/2 mice in frontoparietal and frontal regions 
relative to WT (p < 0.05)
EEG markers were detected prior to any 
symptoms
Absolute theta and delta power lower in R6/2 mice in frontal region relative to 
WT (p < 0.05)
Absolute gamma power higher in R6/2 mice relative to WT (p < 0.01)
Peak theta frequency shifted from 7 to 6 Hz in R6/2 mice relative to WT 
(p < 0.01)
Fisher et al. (17) 2013 R6/2 mice Dural screws qEEG High-frequency beta and gamma (25–60 Hz) absolute power higher in R6/2 
during wake relative to WT (p < 0.05)
Circadian rhythm disturbances were found 
(body temperature, sleep/wake disturbances) 
in R6/2 mice relative to WT, but EEG 
abnormalities were detected earlier
Absolute delta and theta power lower in R6/2 during NREM relative to WT 
(p < 0.05)
Miller et al. (21) 2011 R6/2 mice Striatum LFP Delta and theta relative power lower in R6/2 relative to WT (p < 0.05) None
Gamma relative power higher in R6/2 relative to WT (p < 0.05)
Base search terms included (EEG OR EEG Mapping OR qEEG) AND (Huntington’s Disease OR Huntington’s OR Huntington OR Huntington Disease). Additional terms included biomarker, preclinical, power spectral analysis, neural 
networks, low-resolution electromagnetic tomography (LORETA) (Mouse OR Mice) AND (R6/2 OR zQ175), and rat. Results were restricted to rodents. Information noted includes total number of species examined, the electrode 
recording site and recording measure used, any relevant qEEG-related findings, and correlations of those findings to behavioral and genetic measures.
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hippocampal absolute gamma power in BACHD rats relative 
to WT. However, they were able to improve auditory gating in 
BACHD rats (but not Het or Hom zQ175 mice) to the point 
of eliminating statistically significant differences between the 
BACHD rats and the WT through administration of a phospho-
diesterase 9A inhibitor. Interestingly, absolute gamma power in 
WT rats also was decreased by this inhibitor, eliminating statisti-
cal differences between the BACHD and WT rats. This finding 
indicates pharmacologic activity in the WT rats of unclear signifi-
cance. The treatment had no effect on auditory gating in the WT 
rats and absolute gamma power in BACHD rats was unaffected 
by the treatment. The relevance of these pharmacologic effects 
to research on mHTT lowering compounds is unclear because 
none of these interventions involved administration of an agent 
that is known to be disease modifying. Nevertheless, the findings 
demonstrate that pharmacologic interventions may have distinct 
effects in different preclinical models.
A number of potential biomarkers are reported with some 
consistency across studies. Five of the seven studies in Table 1 
examined the relative differences across all broad frequency 
bands in HD mice. Kantor et al. (19) focused on the effects of 
hypnotic agents on these already-established differences, while 
Nagy et al. focused on absolute gamma power in the context of a 
phosphodiesterase inhibitor. The five remaining studies reported 
a decrease in delta power (absolute power in four of the five 
studies), regardless of the specific mouse model used. Six studies 
(Nagy included) that examined gamma power in mice found a 
higher gamma power in HD mice relative to WT, regardless of 
strain used (absolute power in five of the six studies). Theta power 
was found to be lower in HD models relative to controls in four 
of five mouse studies (absolute power in three of four studies). 
Absolute beta power was found to be higher in HD models rela-
tive to controls in three of five mouse studies.
These rodent studies demonstrate that qEEG biomarkers 
preceded behavioral symptoms in most cases, even when such 
disturbances were minimal (14, 16–21, 24). The only exception 
to this was Kantor et al. (18), where the qEEG biomarkers and 
some behavioral disturbances were concurrently observed dur-
ing the first recordings at 9 weeks of age; it is unknown if qEEG 
biomarkers were present prior to the early behavioral symptoms 
(18). Additionally, the studies indicate that findings from rodent 
preclinical models are readily reproducible, quantifiable, and 
subject to low variability (25–27). While murine models serve 
as an excellent proof-of-concept, they may not accurately reflect 
the distribution of metabolites throughout the brain as seen in 
humans due to both the size of the rodent and large anatomical 
discrepancies between a human and mouse brain (8–10, 28). 
Additionally, while a maximum lifespan of roughly 36  months 
allows for observation of the full disease course in a feasible 
manner, rodent models may not accurately recapitulate the rate 
of disease progression seen in humans (9–11).
Sheep Models
The OVT73 transgenic sheep is a model of emerging interest 
to examine mHTT lowering. This model expresses a complete 
copy of human Htt with a polyglutamine expansion 73 repeats in 
length (9, 29). The model may be particularly useful to evaluate 
the safety, brain biodistribution, and effects of the expanded 
mHTT gene in a large brain. Additionally, recent data suggest 
that the sheep HD model may be helpful in assessing the effects 
of emerging therapies on mHTT aggregation, receptor status in 
striatum, and early behavioral deficits (10). A literature search 
for the OVT73 model indicates that no qEEG results have been 
published in the OVT73 sheep at the time of this review. qEEG 
has been examined, however, in the CLN5 Batten disease sheep 
model (30). Perentos et al. (30) demonstrated that qEEG can be 
used longitudinally in ovine models to characterize brain function 
as well as sleep patterns. They reported that the motor activity of 
rumination is affected in the CLN5 sheep relative to WT. This 
finding was confirmed by Nicol and colleagues (31), indicating 
that rumination can be used as a measure of motor dysfunction 
(31). Both studies demonstrated the feasibility of recording 
qEEG, studying sleep, and examining motor function, supporting 
the use of qEEG in OVT73 HD model. Further characterization 
of this model may be in order, however, prior to initiation of 
qEEG studies. While Reid et al. (32) have demonstrated striatal 
transcripts indicative of gene expression (32, 33) and Handley 
et al. (33) have demonstrated altered brain metabolic activity in 
5-year-old OVT73 sheep (33), Morton et  al. (34) showed that 
the OVT73 sheep exhibit no structural differences using MRI 
relative to the WT sheep, only circadian differences (34), when 
studied until 5 years of age. The lack of onset of obvious brain 
structural changes or motor symptoms suggests the presentation 
of HD in OVT73 may be less severe or incomplete. However, the 
development of qEEG and rumination recording methods in 
the CLN5 sheep supports the usefulness of ovine research and 
supports further development of the OVT73 model. After further 
characterization, ovine models may be poised to help bridge HD 
research from small animal to human models.
Other Animal Models
Relatively little work has been done with non-human primate and 
minipig models of HD, which have only recently been developed 
(8–10, 35–40). The literature search found no results for qEEG 
studies in these models and that behavioral phenotyping is cur-
rently ongoing in minipig models (35–37). A search for studies 
in non-human primates similarly yielded no results, and further 
investigation showed that non-human primate models are cur-
rently undergoing development and verification (9, 38–40). Both 
of these models are still under development and may have poten-
tial in the future to bridge the gap between rodents and humans.
Human Studies
Research on the use of qEEG biomarkers in human subjects 
has included not only spectral frequency analysis as in animal 
models, but also other methods that take advantage of the larger 
size of the human brain and the greater number of electrodes to 
examine sources of electrical activity, regional differences in brain 
activity, and functional network complexity. These include source 
localization techniques such as low-resolution electromagnetic 
tomography (LORETA), topographic brain EEG mapping, and 
network and connectivity analyses (Table 2).
De Tommaso et al. (47) applied three different methods of anal-
ysis (artificial neural network or ANN, Fisher linear discriminant, 
TABLe 2 | Literature review results for qeeG biomarkers in humans.
Reference Year Measure Subjects Control Pre-
HD
HD electrophysiological Finding(s) Clinical correlation(s) CAG-repeat 
correlation
Other
Lazar et al. 
(41)
2015 EEG-PSG 82 36 38 8 5–7 Hz range (theta and alpha–theta border) 
relative power lower in pre-HD and early HD 
during REM relative to controls (p < 0.00125)
Relative power in 5–7 Hz range in HD during REM 
negatively correlated with disease burden score (DBS)
None  
6–7 Hz range (theta and alpha–theta border) 
relative power lower in pre-HD and early HD 
during NREM relative to controls (p < 0.00125)
Piano et al. 
(42)
2015 LORETA 46 23 0 23 Alpha power higher in HD during NREM 
relative to control (p < 0.01)
Delta LORETA power negatively correlated with Unified 
Huntington’s Disease Rating Scale (UHDRS) during wake
None Includes a 
literature 
review table 
that goes 
back further 
than the one 
in this review
Alpha power lower in HD during REM relative 
to control (p < 0.01)
Beta power lower in HD during NREM relative 
to control (p < 0.01)
Alpha, beta, and theta LORETA power positively correlated 
with UHDRS during NREM
Theta power lower in HD during NREM and 
REM relative to control (p < 0.01)
Delta power higher in HD during wake relative 
to control (p < 0.01)
Ponomareva 
et al. (43)
2014 qEEG 58 29 29 0 8–9 Hz range (alpha) relative power lower in 
pre-HD relative to control (p < 0.05)
Alpha, theta, and delta relative power positively correlated 
with DBS in pre-HD
CAG repeat length 
positively correlated 
with delta and theta 
relative power, 4–5 
and 5–6 Hz bin relative 
power
 
7–8 Hz range (alpha–theta border) relative 
power lower in pre-HD relative to control 
(p < 0.01)
Extreme positive correlation between the difference of 
relative power between 7–8 and 4–5 Hz bin and DBS
Negatively correlated 
with alpha relative 
power, 7–8, 9–10, and 
10–11 Hz bin relative 
power
Delta and theta relative power negatively correlated with 
FAS score
Alpha relative power positively correlated with FAS score
Extreme positive correlation between the difference of 
relative power between 7–8 and 4–5 Hz bin and FAS score
Painold et al. 
(44)
2011 LORETA 110 55 0 55 Alpha LORETA power lower in HD relative to 
control (p < 0.05)
Alpha LORETA power positively correlated with Mini Mental 
State Examination (MMSE) score
None Delta power 
observations 
were 
primarily in 
later stages 
of HD
Beta LORETA power lower in HD relative to 
control (p < 0.05)
Theta LORETA power lower in HD relative to 
control (p < 0.05)
Theta and alpha LORETA power negatively correlated with 
UHDRS
Delta LORETA power higher in HD relative to 
control (p < 0.05)
Painold et al. 
(49)
2010 EEG 
Mapping
110 55 0 55 Absolute alpha power lower in HD relative to 
control (p < 0.05)
Absolute alpha power positively correlated with MMSE 
score and negatively with UHDRS
None  
Absolute beta power lower in HD relative to 
control (p < 0.05)
Absolute beta power positively correlated with MMSE and 
UHDRS scores
Absolute theta power higher in HD relative to 
control (p < 0.05)
Absolute delta power positively correlated with MMSE 
score and negatively with UHDRS
(Continued )
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Reference Year Measure Subjects Control Pre-
HD
HD electrophysiological Finding(s) Clinical correlation(s) CAG-repeat 
correlation
Other
Absolute delta power higher in HD relative to 
control (p < 0.05)
Absolute theta power negatively correlated with MMSE 
and UHDRS scores
Hunter et al. 
(45)
2010 qEEG 42 15 3 24 Absolute delta power higher in HD relative to 
control (p = 0.0000001)
Absolute alpha power negatively correlated with MMSE, 
digit symbol, and Stroop reading scores
Relative delta power 
AP gradient negatively 
correlated with CAG-
repeat length
Absolute 
alpha power 
increase 
was only 
significant 
when 
medicated 
patients 
were 
included in 
analysis
Relative alpha anterior–posterior (AP)-gradient 
lower in HD relative to control (p = 0.000004)
Relative alpha AP-gradient positively correlated with 
Burden Pathology Score (BPS) score and negatively with 
Total Functional Capacity (TFC) and Stroop reading scores
Relative delta AP-gradient lower in HD relative 
to control (p = 0.02)
Relative delta AP-gradient positively correlated with TFC 
score and negatively with BPS and Total Motor Symptoms 
scores
Van der 
Hiele et al. 
(46)
2007 qEEG 29 13 16 0 Relative alpha power lower in Pre-HD relative 
to control (p = 0.003)
None None  
Absolute alpha power lower in Pre-HD relative 
to control (p = 0.013)
Theta power unchanged in Pre-HD relative to 
control (p = 0.36)
De 
Tommaso 
et al. (47)
2003 qEEG 33 13 7 13 Absolute alpha power lower in HD relative to 
control (significance not reported)
None None No 
conclusions 
made 
regarding 
Pre-HD
Absolute theta power higher in HD relative to 
control (significance not reported)
Absolute delta power higher in HD relative to 
control (significance not reported)
Base search terms included (EEG OR EEG Mapping OR qEEG) AND (Huntington’s Disease OR Huntington’s OR Huntington OR Huntington Disease). Additional terms included biomarker, preclinical, power spectral analysis, neural 
networks, and LORETA. Results were restricted to humans. Information noted includes recording modality used, the total number of subjects, the number of Huntington’s Disease (HD) subjects, the number of HDGEC/pre-HD 
subjects, the number of control subjects, any relevant qEEG-related findings, and correlations of those findings to clinical and genetic measures.
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and likelihood ratio method) to examine qEEG data collected 
from HD subjects, premanifest HDGECs, and control subjects 
(47). Receiver-operating characteristic curve analysis showed 
that the ANN exhibited the strongest discrimination among 
groups of the three methods used. ANN analyses of HD subjects 
relative to controls showed a decrease in the absolute alpha power 
and an increase in both absolute theta and absolute delta power. 
None of these neurophysiologic measures correlated with any 
clinical or cognitive performance findings tested, including the 
Marsden and Quinn Chorea Severity Scale, Mini-Mental State 
Examination (MMSE), Wechsler Adult Intelligence Scale (WAIS) 
Full Scale IQ, WAIS Verbal IQ, WAIS Performance IQ, Verbal 
Scaled Score, and Block Design Scaled Score. The ANN neural 
scores for premanifest HDGECs did correlate with the predicted 
time to onset, indirectly suggesting an association between qEEG 
measures and the number of CAG repeats for those subjects.
Van der Hiele et al. (46) examined qEEG in control and pre-
manifest HDGEC subjects in the context of a working memory 
task (46). They found a decrease in both relative and absolute 
alpha power compared to controls during the working memory 
task, but no differences were found during the resting state. No 
other statistically significant qEEG markers were found. The 
detected changes in alpha power during the working memory 
task had no clinical or pathophysiological correlates, including 
performance on the working memory task.
Hunter et  al. (45) examined the anterior–posterior (AP) 
gradients of qEEG power in addition to global measures of 
relative and absolute qEEG power (45). This study replicated the 
global decrease in delta power in HD subjects relative to controls 
observed in prior reports (47, 48). This study further represented 
one of the first reports to examine regional qEEG patterns and 
found loss of the normal AP gradients of both alpha and delta 
relative power in HD subjects as compared to controls. Whereas 
relative alpha power normally shows a posterior-dominant dis-
tribution, loss of this posterior dominance was associated with 
greater disease burden and poorer performance as assessed by 
the Burden Pathology Score, Total Functional Capacity (TFC) 
score, and Stroop reading score measures. Regarding relative 
delta power, loss of the normal anterior-dominant distribution 
was correlated with lower TFC, higher disease burden (BPS), and 
higher total motor symptoms. Importantly, the delta relative AP 
gradient was significantly associated with the number of CAG 
repeats: loss of the relative delta AP gradient correlated with a 
higher number of CAG repeats. Furthermore, the relative alpha 
AP gradient was examined in three premanifest subjects and the 
gradient appeared to decrease in relation to estimated years until 
onset. Hunter et al. (45) was the first study to examine relative AP 
gradients in HD and the first to find a qEEG biomarker directly 
correlated to the number of CAG repeats.
Painold et al. (49) used qEEG mapping to examine spectral 
power, but with a larger sample size than previous qEEG HD 
studies in humans (49). They reported a decrease in both abso-
lute alpha and beta power and an increase in both absolute theta 
and delta power relative to controls. Additionally, the frequency 
centroid of delta, theta, beta, and total power was decreased 
in HD relative to controls. Clinical correlates were also found: 
alpha and delta power positively correlated with MMSE scores 
and negatively with Unified Huntington’s Disease Rating Scale 
(UHDRS) scores, beta power positively correlated with both 
MMSE and UHDRS scores, and theta power negatively correlated 
with both MMSE and UHDRS scores. However, no correlates 
with CAG repeat length were reported. In a subsequent study, 
this group examined the same frequency bands using LORETA 
instead of EEG mapping as in the 2010 study (44). They discovered 
that theta, alpha, and beta LORETA spectral power decreased 
globally across early and late stages of HD, but increases in delta 
LORETA spectral power were only present in later stages of HD, 
and primarily in the right orbitofrontal cortex. The decrease in 
theta LORETA spectral power differs from Painold et al.’s 2010 
study (44). However, theta and alpha power were still negatively 
correlated with UHDRS scores, and alpha power was positively 
correlated with MMSE scores. The source of the seemingly con-
flicting observations regarding theta power observations between 
Painold et al. (49) and Painold et al. (44) are unclear, as it appears 
that the same pool of subjects was used in both studies. There 
are, however, some differences in the regions where changes in 
theta power were observed; additionally, differences in analytical 
methods could explain the seeming discrepancy as LORETA 
utilizes a different transformation than EEG mapping to allow 
for source attribution of current density. Therefore, more global 
measures that are detected in EEG mapping are not necessarily 
observed in LORETA and vice-versa (42, 44, 49). Even so, both 
studies performed by Painold and colleagues identified qEEG 
measures that had significant association with clinical measures 
in HD.
Ponomareva et  al. (43) approached the use of qEEG as a 
biomarker of HD in premanifest HDGECs and examined 1Hz 
frequency bins within the traditionally examined wave bands 
in premanifest and control subjects. It was also the first study 
to focus solely on pre-HD subjects using qEEG biomarkers 
(43). They found no significant differences between the relative 
power of pre-HD and control subjects when examining the 
broad frequency bands. However, relative power was found 
to decrease in pre-HD subjects in the 8–9  Hz sub-band and 
even more in the 7–8  Hz sub-band. Additionally, although no 
significant differences were found between the premanifest and 
control subjects in the broad bands, both delta and theta relative 
power demonstrated positive correlation with the number of 
CAG repeats within the pre-HD group, and relative alpha power 
demonstrated a negative correlation. The number of CAG repeats 
also correlated positively with the 4–5 and 5–6 Hz frequency bins, 
and negatively with the 10–11, 7–8, and 9–10  Hz bins. Highly 
significant positive correlation was observed between the Disease 
Burden Score (DBS) and the difference of relative power between 
the 7–8 and 4–5 Hz bins. The broad frequency bands were also 
found to correlate with clinical measures in premanifest subjects. 
Alpha, theta, and delta relative power in pre-HD subjects were 
all found to positively correlate with DBS. Word fluency (FAS) 
scores negatively correlated with delta and theta relative power, 
and positively with alpha relative power. The 8–9 Hz frequency 
bin relative power demonstrated positive correlation with FAS 
score, and the 4–5 and 5–6 Hz bins demonstrated negative cor-
relation. The difference between the 7–8 and 4–5 Hz bin relative 
power again demonstrated highly significant positive correlation 
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in FAS scores. Of note is that the investigators excluded frequency 
bands below 2 Hz, so that lower frequency delta activity was not 
examined. This affects the definition of the delta band as well as 
the total spectral power measured. Therefore, the relative power 
measurements found in Ponomareva’s study may differ from find-
ings in other studies by virtue of the 2 Hz high-pass frequency 
cutoff. As noted, many of the frequency bands (both broad bands 
and 1 Hz bins) showed correlation with both the number of CAG 
repeats and clinical measures in pre-HD subjects. These EEG 
frequencies are of particular interest when identifying potential 
biomarkers. Further study in symptomatic HD subjects and 
HDGEC subjects is necessary to validate the use of these sub-
bands as biomarkers.
Piano et al. (42) examined EEG in HD subjects using LORETA 
(42). While not as large as the studies from Painold and col-
leagues, Piano et al. provided valuable replication and examined 
the power spectrum characteristics in both wake and sleep states. 
Piano et  al. found that during the wake state, delta LORETA 
power was observed to increase bilaterally in HD patients, though 
more strongly in the right hemisphere. During NREM sleep in 
HD subjects, alpha LORETA power was observed to increase 
bilaterally, theta LORETA power was observed to decrease bilat-
erally, and beta LORETA power was observed to decrease in the 
left hemisphere relative to controls. During REM sleep in HD 
subjects, alpha and theta LORETA power were both observed to 
decrease bilaterally compared to controls. EEG spectral LORETA 
power in Brodmann area 4 was associated with disease duration 
during wake and REM states and UHDRS score during NREM. 
Delta, theta, and left hemisphere beta LORETA power during the 
wake state were all positively associated with disease duration, 
while only right hemisphere delta was positively associated with 
UHDRS during wake. Theta, alpha, and beta LORETA power 
all correlated positively with UHDRS during NREM, and right 
hemisphere alpha LORETA power positively correlated with 
disease duration during NREM. During REM, alpha LORETA 
power again positively correlated with disease duration.
Lazar et al. (41) examined sleep and metabolic characteristics 
in premanifest and early HD subjects relative to controls and is the 
first study to examine sleep quality and metabolic markers in pre-
HD subjects (41). No metabolic differences were found between 
the pre-HD and control subjects using x-ray absorptiometry, 
whole body indirect calorimetry, and blood sampling (for testos-
terone, cortisol, vitamin D, and leptin). However, differences were 
discovered in the principal component analysis of the qEEG data 
and sleep measures. Polysomnography measurements revealed 
that pre-HD and early HD subjects had objectively worse sleep 
quality than controls, and early HD subjects had worse quality of 
sleep compared to premanifest subjects. qEEG analysis showed a 
relative power increase in early HD subjects in the 5–7 Hz (theta/
alpha–theta border) range compared to controls. The relative 
power of the 4–7 Hz range negatively correlated with DBS during 
REM sleep. Lazar et  al. and Ponomareva et  al. both examined 
smaller frequency bins, and they both found correlates in the 
alpha–theta border range (41, 43).
Many of the human studies identified potential biomarkers 
in similar frequency bands, although the specific changes within 
these bands is not entirely consistent. Four (45–47, 49) of the 
eight studies examined absolute power measures, three in HD 
subjects (45, 47, 49) and one in premanifest subjects (46). Global 
absolute alpha power was significantly lower in HD vs. controls 
in two of three HD studies (47, 49). Absolute alpha power was 
reported to decrease in premanifest subjects (49). Absolute delta 
power was found to increase in all three studies of HD subjects 
(45, 47, 49), but not in premanifest subjects (46). Absolute theta 
power was greater in HD relative to controls in two of the three 
studies (47, 49), but not in either the third (45) or in premanifest 
subjects (46). Absolute beta power was only observed to increase 
in one of the studies of HD subjects (49). Two of eight studies 
examined the relative power of 1 Hz frequency bins, particularly 
near the alpha–theta border (41, 43). One examined premanifest 
and early HD subjects relative to controls (43) and the other 
premanifest subjects relative to controls (41). Significantly, both 
found decreases in ranges near the alpha–theta border, though 
the specific bins that decreased were not consistent across the 
studies (41, 43). One of these studies excludes any signals under 
2 Hz, making comparison of results across the two studies more 
difficult (43).
Using different analytic methods, two of the eight studies 
examined LORETA power (42, 44), derived from current-source 
density across Brodmann areas. However, Painold et al. examined 
LORETA during a vigilance state, while Piano et  al. examined 
LORETA during NREM and REM sleep in addition to waking 
state. Delta LORETA power was higher in HD relative to controls 
during wake in both studies. While both studies have other results 
of interest, there was no overlap in other findings, as Piano et al. 
(42) found no other differences in HD relative to controls during 
wake, and Painold et al. (44) did not examine NREM and REM 
states.
DiSCUSSiON
The literature from preclinical and human studies suggest that 
qEEG measures constitute a reliable and reproducible biomarker 
to detect brain dysfunction in preclinical and human studies 
of the HD phenotype, as well as in HDGECs. Several potential 
biomarkers appear to replicate across human studies. One of the 
most replicable findings was an increase in absolute delta power, 
which has been reported frequently in HD subjects (42, 44, 45, 
47, 49) although not in premanifest subjects (41, 43, 46). In 
premanifest HDGECs, the relative power of specific sub-bands 
has been observed to be decreased across multiple studies (41–44, 
46, 47, 49). These sub-bands are at the border between alpha and 
theta frequencies (41, 43). These findings would suggest that in 
characterizing the process of phenoconversion in HDGECs, shifts 
in rhythmic oscillations between the alpha and theta frequency 
ranges may be particularly useful biomarkers. Hunter et al. (45) 
examined the AP gradients of relative qEEG power and found 
two more potentially useful biomarkers in the alpha and delta 
frequency bands (45). The effect of HD disease progression on 
rhythmic oscillatory activity in the delta, theta, and alpha bands 
constitutes a highly plausible disease biomarker for increasing 
mHTT burden: oscillations in this frequency range are modulated 
by corticothalamic circuits (50, 51), and in particular, by thalamic 
nuclei that are known to show structural changes with disease 
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progression (52, 53). Different thalamic nuclei regulate rhythmic 
oscillations in anterior and posterior brain regions, which could 
explain why the AP gradient would shift during disease progres-
sion as different thalamic nuclei become involved in the illness. 
Other potential human biomarkers are in the higher frequency 
range, where beta absolute and LORETA power were observed 
to decrease in HD subjects (42, 44, 49). However, the decrease 
in beta power was not found in most studies examined (41, 43, 
45–47). High-frequency power biomarkers have been correlated 
with clinical measures in at least one of the studies that examined 
them.
One of the most significant findings from the human bio-
marker literature is the correlation of specific qEEG variable 
with the number of CAG repeats: the relative delta AP gradi-
ent from Hunter et al. negatively correlated with CAG repeat 
length, the relative delta and theta power frequency bins from 
Ponomareva et  al. positively correlated with the number of 
repeats, and the relative alpha power from Ponomareva et al. 
negatively correlated with the number of repeats (43, 45). 
Correlations with repeat length now have been reported in 
both symptomatic and premanifest subjects and are consistent 
with the fact that qEEG measures can be used to differentiate 
HDGECs from healthy controls before the onset of symptoms. 
This finding suggests that the production of mHTT has effects 
on neurophysiologic function even in advance of phenocon-
version and offers the promise that qEEG biomarker might be 
useful for monitoring the efficacy of mHTT lowering therapies 
in clinical trials.
Inconsistencies or failure to replicate results across human 
biomarker studies may result from several factors. Studies 
frequently either do not report or statistically account for the 
medication status of their subjects. Psychotropic medication may 
affect qEEG power or frequency results, although Hunter and 
colleagues reported no significant effect of the most common 
medications. Other factors not commonly reported include age of 
onset, number of CAG repeats, and duration of symptoms. Such 
factors should be routinely examined in future studies.
For the purposes of treatment development, it would be useful 
for comparable qEEG biomarkers to be measureable in preclini-
cal and clinical studies. The greatest body of preclinical work has 
been performed in rodent (primarily murine) models. There is a 
good consistency in rodent models in detecting changes in delta 
and theta power in HDGECs and affected animals. Most preclini-
cal studies have reported decreased delta and theta power relative 
to WT animals, while human studies have reported increased 
power in the delta band but decreased power in the theta band 
relative to controls. Several factors may account for this seem-
ing discrepancy in results. First, animal studies most commonly 
report absolute power (i.e., total energy output) differences, while 
the most robust differences in humans have been in relative power 
measures (i.e., proportion of energy in a band relative to the entire 
frequency spectrum). It is common in brain disease for the qEEG 
power to decrease in a slow wave band, but for the proportion 
of total power in that band to increase. As discussed above, 
human studies have reported shifts in power between the theta 
and alpha bands with phenoconversion, suggesting that relative 
power measures may be best suited to the purpose of biomarkers 
for mHTT lowering compounds. Future studies should compare 
absolute and relative power measures in murine models.
Second, the conditions in which qEEG recordings are per-
formed in preclinical and human studies differ considerably. 
While human studies most commonly have been performed in 
the eyes-closed resting state or during a specific cognitive task, 
rodent studies have been recorded in a variety of waking condi-
tions (resting or vigilance) or in the sleep state. Brain oscillatory 
patterns differ considerably across these conditions, and it is dif-
ficult to translate a specific waking state in mice to one in humans. 
It could be possible to compare sleep qEEG biomarkers in mice 
and humans, but little work has been done with qEEG during 
sleep in clinical populations.
Third, it is important to note that the frequency and location 
of oscillatory biomarkers is inherently different in rodent than 
human brain. Rodents do not have a posterior-dominant rhythm 
in the alpha frequency range as do humans, with broader theta 
frequency rhythms being more dominant. Rodents also have far 
less prefrontal cortex than do humans and a different pattern of 
mapping to thalamic nuclei that regulate rhythmicity. Therefore, 
there will be differences between species in both where and how 
qEEG biomarker differences can be detected. Owing to the small 
head size, rodent studies commonly record from only 1–2 cortical 
electrode locations in the anterior or central region. The largest 
qEEG biomarker differences between HD subjects or HDGECs 
and controls have been detected using topographic approaches 
to data analysis (i.e., regional brain mapping, AP gradients, and 
LORETA). It will be important for rodent studies of mHTT 
lowering biomarkers to measure qEEG in both anterior and pos-
terior electrode locations, as well as in thalamic nuclei, in order 
to attempt to detect topographic effects. It also will be important 
to look for shifts in relative power oscillatory frequency rather 
than absolute power, given the fact that simple alpha and theta 
measurements do not translate across species.
Fourth, significant differences in high-frequency (beta and 
gamma) activity have been detected in rodent, but not in human 
studies. Several factors may account for these differences. Beta 
activity is easily measureable in both humans and animals, but 
in humans, it is more susceptible to recording artifact (e.g., 
muscle activity) as well as medication effects (i.e., benzodiaz-
epines, which are commonly used by HD subjects to promote 
sleep). Gamma activity is a very low amplitude oscillation that 
is readily detected in animals with electrodes placed adjacent 
to or in the cortex, but is inherently difficult to measure in 
humans with extracranial scalp recordings that are susceptible 
to artifact from muscle tissue between the electrode and the cer-
ebral sources. Beta frequency biomarkers may be detectable in 
clinical studies, but gamma frequency biomarkers may be better 
suited to rodent models, which can record gamma activity with 
greater reliability through the use of indwelling dural screw or 
cortical electrodes.
While qEEG biomarkers fulfill most of the criteria of fit-for-
purpose biomarkers for mHTT lowering compounds, no studies 
yet have conclusively established a link between mHTT burden 
and a qEEG measure. And, while at least two studies have shown an 
association between a pharmacologic treatment intervention and 
normalization of a qEEG biomarker, no study has demonstrated 
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sensitivity of a qEEG biomarker to an mHTT lowering interven-
tion. To further establish the suitability of these biomarkers, 
longitudinal and cross-sectional research should be performed 
to replicate and extend previous findings. Replication would 
entail longitudinal studies examining the correlation of these 
biomarkers to both disease severity and number of CAG repeats 
in preclinical rodent models and human subjects. Extension 
of previous research would involve translation of preclinical 
biomarkers from rodents to humans by more precisely mapping 
the location and frequency bands that could establish equivalency 
of findings across species. A further extension also should be to 
suppress mHTT expression in rodents and observe the response 
of the biomarkers recorded in both cortical and subcortical areas 
known to be affected by disease progression. These biomarkers 
then could be examined in the context of other animal models 
such as sheep, minipigs, or non-human primates. This type of 
characterization would provide greater understanding of disease 
mechanism, validation of the biomarkers, and more precise 
definition of which biomarkers are fit-for-purpose for mHTT 
lowering studies in preclinical and human trials.
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